Get the Stockscreener App
0.5706
2.09%
0.006
Scilex Holding Company stock is traded at $0.5706, with a volume of 302.67K.
It is up +2.09% in the last 24 hours and down -41.18% over the past month.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
See More
Previous Close:
$0.5646
Open:
$0.58
24h Volume:
302.67K
Relative Volume:
0.16
Market Cap:
$79.39M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-0.9491
EPS:
-0.6012
Net Cash Flow:
$-21.04M
1W Performance:
-15.24%
1M Performance:
-41.18%
6M Performance:
-48.07%
1Y Performance:
-39.17%
1-Day Range:
$0.5604
$0.5831
1-Week Range:
$0.5377
$0.7348
52-Week Range:
$0.5377
$2.63
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
(650) 516-4310
Address
960 SAN ANTONIO ROAD, PALO ALTO
Compare SCLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SCLX | 0.5764 | 79.39M | 46.74M | -114.33M | -21.04M | -0.6012 |
| LLY | 744.83 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.30 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.24 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 168.10 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 97.39 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Scilex Holding Company Stock (SCLX) Latest News
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 1419, 2024 - The Manila Times
Scilex Holding Company Announces Presentation of Data at - GlobeNewswire
Scilex Holding Company Announces Presentation of Data at the 2024 American College of ... - The Bakersfield Californian
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024 - Yahoo Finance
Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m - Simply Wall St
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Pre - The Manila Times
Scilex Holding Plans Merger to Boost Semnur Value - TipRanks
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of - GlobeNewswire
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces - The Bakersfield Californian
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary - Barchart
Chipotle Mexican Grill (CMG-N) QuotePress Release - The Globe and Mail
Scilex Pharmaceuticals announces end of phase II meeting with FDA for SP-103 - MSN
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Scilex holding's CEO Jaisim Shah buys $31,670 worth of shares - Investing.com India
A W Food Services of Canada Inc (AW-T) QuotePress Release - The Globe and Mail
Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock - Yahoo Finance
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, - The Manila Times
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of - GlobeNewswire
Scilex holding's CEO Jaisim Shah buys $31,670 worth of shares By Investing.com - Investing.com Canada
Jaisim Shah Acquires 32,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock - ForexTV.com
Scilex Holding Company, Following its Prior Announcement of - GlobeNewswire
Scilex Holding Sets Dividend for Preferred Stock Exchange - TipRanks
Scilex Holding Company sets November 7, 2024 as the Record - GlobeNewswire
Alliance Global Partners Begins Coverage on Scilex (NASDAQ:SCLX) - Defense World
Scilex gains on spinoff plans for pharma subsidiary - MSN
Scilex director Followwill Dorman buys $990 in common stock By Investing.com - Investing.com South Africa
Scilex director Followwill Dorman buys $990 in common stock - Investing.com
Scilex director Chun Jay acquires $4,750 in common stock - Investing.com
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Scilex Holding (NASDAQ:SCLX) Director Yue Alexander Wu Acquires 20,000 Shares - MarketBeat
Scilex holding's executive chairperson Ji Henry buys $9,710 in stock - Investing.com
Scilex director Wu Yue Alexander buys $18,992 in common stock By Investing.com - Investing.com South Africa
Scilex director Wu Yue Alexander buys $18,992 in common stock - Investing.com India
Scilex holding's executive chairperson Ji Henry buys $9,710 in stock By Investing.com - Investing.com UK
Scilex director Chun Jay acquires $4,750 in common stock By Investing.com - Investing.com Australia
Scilex CFO Stephen Hoi purchases $6,499 in common stock - Investing.com India
Scilex Holding's CEO Jaisim Shah purchases $29,751 in common stock - Investing.com India
Scilex Holding's CEO Jaisim Shah purchases $29,751 in common stock By Investing.com - Investing.com Canada
Jaisim Shah Purchases 30,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
Scilex CFO Stephen Hoi purchases $6,499 in common stock By Investing.com - Investing.com UK
Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate - Benzinga
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Scilex Holding looks to separate Scilex Pharma through potential spinout, IPO - FiercePharma
Scilex stock gains on spinoff plans (SCLX:NASDAQ) - Seeking Alpha
Scilex Holding explores spinoff for subsidiary Scilex Pharma - Investing.com
Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securit - The Manila Times
Scilex Holding explores spinoff for subsidiary Scilex Pharma By Investing.com - Investing.com South Africa
Scilex Holding Company Announces that its Board of - GlobeNewswire
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Betwee - The Manila Times
Scilex Holding Company Stock (SCLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):